Posted by Michael Wonder on 02 Oct 2023
Avenge Bio receives FDA fast track designation for AVB-001, a novel cell therapy leveraging the LOCOcyte immunotherapy platform
2 October 2023 - Regulatory designation includes platinum-resistant, high grade serous adenocarcinoma of the ovary, primary peritoneum or fallopian tube.
Avenge Bio today announced that the US FDA has granted fast track designation for AVB-001 for treatment of patients with relapsed resistant/refractory ovarian cancer.
